fosmidomycin

Subscribe to Selected New Research on fosmidomycin

28 relevant articles (8 outcomes, 10 trials/studies) found for this Bio-Agent

Description: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source

Also Known As:

3-(N-formyl-N-hydroxy)aminopropylphosphonic acid; FR-31564; fosfidomycin; fosmidomycin monoammonium salt; fosmidomycin monopotassium salt; fosmidomycin monosodium salt; fosmidomycin sodium salt; (3-(formylhydroxyamino)propyl)phosphonic acid, monosodium salt

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Organophosphorus Compounds: 126

Phosphonic Acids: 77

Fosfomycin: 415

fosmidomycin: 28

Experts

1.	Jomaa, Hassan: 7 articles (08/2006 - 12/2002)
2.	Issifou, Saadou: 6 articles (05/2007 - 12/2002)
3.	Kremsner, Peter G: 6 articles (05/2007 - 12/2002)
4.	Wiesner, Jochen: 6 articles (08/2006 - 12/2002)
5.	Borrmann, Steffen: 6 articles (08/2006 - 12/2002)
6.	Adegnika, Ayola A: 5 articles (08/2006 - 12/2002)
7.	Matsiegui, Pierre-Blaise: 5 articles (08/2006 - 12/2002)
8.	Oyakhirome, Sunny: 4 articles (05/2007 - 11/2004)
9.	Hutchinson, David: 4 articles (01/2007 - 02/2003)
10.	Ramharter, Michael: 3 articles (05/2007 - 11/2004)

Related Diseases

1.	Malaria 12/14/2002 - "These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more." 09/01/2005 - "Fosmidomycin is effective against malaria, but it needs to be given for > or =4 days when used alone" 08/01/2003 - "This compound, fosmidomycin, has been shown to be somewhat effective in treating Plasmodium falciparum, the parasite responsible for malaria" 05/19/2005 - "This target has been characterized as having potential in the treatment of malaria with fosmidomycin, an established DXR inhibitor, presently in clinical trials" 01/01/2007 - "The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model" Order ALL the reference details at left...
2.	Infection 02/01/2003 - "Fosmidomycin is an effective and safe antimalarial drug, although its use as a single agent is restricted by the occurrence of recrudescent infections" 01/01/2003 - "Effect of fosfidomycin on development of various infections in mice]" 03/01/2004 - "Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children." 03/01/2004 - "METHODS: We conducted a randomized, controlled, open-label study to evaluate the efficacy and safety of fosmidomycin combined with clindamycin (n=12; 30 and 5 mg/kg body weight every 12 h for 5 days, respectively), compared with fosmidomycin alone (n=12; 30 mg/kg body weight every 12 h for 5 days) and clindamycin alone (n=12; 5 mg/kg body weight every 12 h for 5 days) for the clearance of asymptomatic Plasmodium falciparum infections in schoolchildren in Gabon aged 7-14 years" 01/01/1980 - "The therapeutic efficacy of FR-31564 in experimental infections in mice was superior to that of fosfomycin in infections due to most Gram-negative bacteria used, and was similar to that of gentamicin in infections due to Citrobacter freundii, Proteus rettgeri and Proteus inconstans B" Order ALL the reference details at left...
3.	Falciparum Malaria (Plasmodium falciparum Malaria) 06/01/2003 - "In recent clinical studies it was shown that fosmidomycin is effective in curing uncomplicated Plasmodium falciparum malaria in humans" 02/01/2003 - "In this open-label, uncontrolled trial, the efficacy and safety of fosmidomycin, in an oral dose of 1,200 mg every 8 h for 7 days, were evaluated in the treatment of acute uncomplicated Plasmodium falciparum malaria in 20 adult subjects in Gabon and Thailand" 09/01/2002 - "In a recent clinical study, fosmidomycin was effective and well tolerated in the treatment of patients with acute uncomplicated Plasmodium falciparum malaria but resulted in an unacceptably high rate of recrudescence" 01/01/2007 - "BACKGROUND: The study investigated the pharmacokinetics of fosmidomycin when given alone and in combination with clindamycin in patients with acute uncomplicated falciparum malaria" 01/01/2007 - "Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria." Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 01/01/1982 - "After i.v. administration of 10 mg/kg of body weight, [14C]-fosmidomycin was excreted mainly in the urine (about 90% of dose within 72 h); and only a little was excreted in the expired air (14CO2) and bile of rats (less than 1% of dose), which suggested the absence of enterohepatic circulation" 08/01/2006 - "We conducted a single-arm study to improve the precision of efficacy estimates for an oral 3-day fixed-ratio combination of fosmidomycin and clindamycin at 30 and 10 mg/kg of body weight, respectively, every 12 hours for the treatment of uncomplicated P" 09/01/2005 - "We conducted a study of 50 children with Plasmodium falciparum malaria to evaluate the safety and efficacy of consecutively shortened regimens of artesunate-fosmidomycin (1 to 2 mg/kg of body weight and 30 mg/kg of body weight, respectively; doses given every 12 hours)" 03/01/2004 - "METHODS: We conducted a randomized, controlled, open-label study to evaluate the efficacy and safety of fosmidomycin combined with clindamycin (n=12; 30 and 5 mg/kg body weight every 12 h for 5 days, respectively), compared with fosmidomycin alone (n=12; 30 mg/kg body weight every 12 h for 5 days) and clindamycin alone (n=12; 5 mg/kg body weight every 12 h for 5 days) for the clearance of asymptomatic Plasmodium falciparum infections in schoolchildren in Gabon aged 7-14 years" 11/01/2004 - "falciparum malaria in Gabon to evaluate the efficacy and safety of an oral combination of fosmidomycin-clindamycin of 30 mg/kg and 10 mg/kg of body weight, respectively, every 12 h" Order ALL the reference details at left...
5.	Tuberculosis 01/01/2008 - "tuberculosis and the fast-growing, saprophytic Mycobacterium smegmatis; both species were resistant to fosmidomycin to a high level" 12/01/2005 - "tuberculosis resistance to fosmidomycin is not due to intrinsic properties of Rv2870c, and the enzyme appears to be a valid drug target in this pathogen." 01/01/2003 - "Positive effect on mice with chronic form of tuberculosis was not observed when the animals were given 1 mg of fosmidomycin per capita twice a day" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Clindamycin (Cleocin)
2.	artesunate
3.	Gentamicins (Gentamicin)
4.	Fosfomycin
5.	Urocortins
6.	Brain Natriuretic Peptide (Natrecor)
7.	Succinic Acid (Succinate)
8.	Ritonavir (Norvir)
9.	Lamivudine (3TC)
10.	Chaperonin 10

Best Treatments:
Research Summary Report
on Malaria

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1048 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>